Skip to main content
. Author manuscript; available in PMC: 2018 Mar 13.
Published in final edited form as: Obesity (Silver Spring). 2016 Nov 2;25(1):155–165. doi: 10.1002/oby.21701

Figure 7. Supra-pharmacological dose of OCA (10mg/kg) failed to improve metabolic and hepatic indices in foz/foz mice with NASH.

Figure 7

(A) Body weight gain, (B) fasting blood glucose (FBG), (C) serum insulin, (D) HOMA-IR, (E) liver weight, (F) liver histology by blinded expert pathologist (MMY) (I, representative pictures; ii, macro-steatosis; iii, inflammation; iv, ballooning; and v, overall NAFLD activity [NAS] score) in atherogenic diet-fed foz/foz mice vs. Wt, with or without OCA treatment. Data are mean ± SEM (n=8/gp). *P<0.05 vs. genotype-matched control (treatment effect), δP<0.05 vs. treatment-matched control (genotype effect).